Kardigan Financial Statements
NASDAQ: KARDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.67+0.47 (+3.31%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kardigan has no annual income statement on file yet, so quarterly figures are shown instead.
Kardigan revenue and earnings
Kardigan reported a net loss of $116.2 million. Diluted earnings per share came in at -$4.61.
Summary generated from market data by MetaCap's automated system. Methodology
Kardigan income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q? 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Operating Expenses | 118.76M | — | 57.13M | — |
| Research & Development | 56.37M | — | 35.84M | — |
| Operating Income | -118.76M | — | -57.13M | — |
| Other Income (Expense) | -2.52M | — | 320.00K | — |
| Pretax Income | -116.24M | — | -57.45M | — |
| Income Tax | 0 | — | 0 | — |
| Net Income | -116.24M | -56.07M | -57.45M | -18.02M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -4.61 | — | -4.64 | — |
| EPS (Diluted) | -4.61 | — | -4.64 | — |
| Shares Outstanding (Basic) | 25.20M | — | 12.38M | — |
| Shares Outstanding (Diluted) | 25.20M | — | 12.38M | — |
| EBITDA | -118.36M | — | -57.02M | — |
This table shows 4 quarterly periods of Kardigan's income statement, from Q2 2026 back to Q? 2025, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow KARD's reporting calendar. What is a income statement?